Diacinti D, Salabè G B, Olivieri A, D'Erasmo E, Tomei E, Lotz-Salabè H, De Martinis C
Istituto di Clinica Medica II, Università di Roma, La Sapienza.
Minerva Med. 1992 Nov;83(11):745-51.
The efficacy of treatment with TSH suppressive doses of L-thyroxine was evaluated by echography in 35 patients with euthyroid nodular goiter. Patients have been subdivided in two groups comparable for sex age and size of the goiter. Sixteen patients were treated for nine months with suppressive doses of thyroxine and nineteen were followed without therapy as control. Patients in treatment were then followed up for additional 9 months without therapy. The mean decrease of thyroid volume at nine months was 25% (27 +/- 10 ml vs 20 +/- 8 ml; p < 0.01). After discontinuation of treatment thyroid volume increased and had returned to base line values after nine months of follow up. In the control group mean thyroid volume had increased by 17.7% at nine months (28 +/- 17 vs 33 +/- 19 ml; p < 0.001). Thyroid nodules in response to thyroid hormone treatment showed a variable behaviour: 30.7% (4/13) of the nodules responded to the therapy with a reduction > to 25% at the ninth month; the remaining nodules were insensitive to the therapy. In conclusion suppressive thyroxine treatment is effective in reducing the goiter, nodules instead are only in part sensitive to the treatment. Thyroxine therapy of euthyroid nodular goiter must be followed for long term since upon thyroxine discontinuation there is a prompt reappearance of the goiter.
采用超声检查评估了35例甲状腺功能正常的结节性甲状腺肿患者接受促甲状腺素抑制剂量左甲状腺素治疗的疗效。根据性别、年龄和甲状腺肿大小将患者分为两组,两组具有可比性。16例患者接受了9个月的甲状腺素抑制剂量治疗,19例作为对照未接受治疗,随访观察。接受治疗的患者随后又随访了9个月,期间未接受治疗。9个月时甲状腺体积平均减少了25%(27±10 ml对20±8 ml;p<0.01)。停止治疗后,甲状腺体积增加,随访9个月后恢复到基线值。对照组9个月时甲状腺体积平均增加了17.7%(28±17对33±19 ml;p<0.001)。甲状腺结节对甲状腺激素治疗的反应表现各异:30.7%(4/13)的结节在第9个月时对治疗有反应,体积缩小>25%;其余结节对治疗不敏感。总之,抑制性甲状腺素治疗在缩小甲状腺肿方面有效,而结节仅部分对治疗敏感。甲状腺功能正常的结节性甲状腺肿患者的甲状腺素治疗必须长期进行,因为停止甲状腺素治疗后甲状腺肿会迅速复发。